Botox: An Advancement In Dentistry – An Overview

  • Pragathi R. Bhat Department of Periodontics, SDMCDSH – Dharwad(India)
  • Palak Janiani Department of Periodontics, SDMCDSH-Dharwad(India).
  • Vijay A. Trasad Department of Pedodontics & Preventive Dentistry, SDMCDSH –Dharwad(India)
Keywords: Botulinium toxin A, minimally invasive, muscle related disorder, esthetics

Abstract

Botox has been used in the medical field since 1987 principally for its cosmetic treatment of wrinkles on the face and for its therapeutic uses in the management of strabismus, cervical dystonia, blehpharospasm and juvenile cerebral palsy amongst other disorders.  The toxin used is botulinium toxin A (BTX-A), which is a neurotoxin, extracted from the anerobic bacteria -Clostridium botulinium. These BTX-A molecules act by inhibiting the release of acetylcholine from presynaptic vessels at the nerve terminals leading to an inhibition of muscle contraction. A growing number of dental surgeons have now been using this toxin as a part of their armamentarium for the management of various muscle-related dental disorders like bruxism, massetric hypertrophy, myofacial pain, trismus, TMJ disorders and for retraining muscles during orthodontic treatment. This procedure has also been found to be a minimally invasive, safe and reproducible alternative to surgery for perioral esthetic enhancement, which includes treating high lip-line cases, gummy smiles and lip augmentation. Pleasing and promising results have been obtained with this technique showing none or mild and transient side effects.DOI:10.21276/AOHDR.1886 

References

1. Patel D, Mehta F, Trivedi R, Thakkar S, Suthar J. Botulinum Toxin and Gummy Smile – A Review. IOSR Journal of Dental and Medical Sciences. 2013; 4(1):1-5.

2. Vaghamshi M, Mahadevia S, Daruwala N and Krishnamurthy. “Botox”- A new vista, in the envelope of esthetic dentistry. The Journal of Ahmedabad Dental College and Hospital 2010; 1(1): 29-34.

3. Nayyar P, Kumar P, Nayyar PV and Singh A. “Botox: Broadening the Horizon of Dentistry”. Journal of Clinical and Diagnostic Research 2014; 8(12): 25-29.

4. Azam A, Manchanda S, Thotapalli S and Kotha SB. “Botox Therapy in Dentistry: A Review”. Journal of International Oral Health 2015; 7:103-105.

5. Frank J. Erbguth. “From poison to remedy: the chequered history of botulinum toxin”. Journal of neural transmission 2008; 115: 559-65.

6. Fenicia L, Franciosa G, Pourshaban M, Aureli P. “Intestinal toxemia botulism in two young people, caused by Clostridium butyricum type F”.Clin Infect Dis.1999;29: 1381-7.

7. Harvey SM, Sturgeon J, Dassey DE. “Botulism due to Clostridium baratii type F toxin. J Clin. Microbiol. 2002;40:2260-2.

8. Meunier FA, Schiavo G. Molgo J. “Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission”. J Physiol (Paris). 2002; 96 (1-2): 105-13.

9. Aoki KR. “Evidence for antinociceptive activity of botulinum toxin type A in pain management”. Headache. 2003;43:S9-15.

10. Edwards, Michael (2006). “Anal fissure”. Dumas Ltd. Retrieved August 21,2010.

11. Freund B, Finkelstein I and Ko G. “Review of the applications of Botulinum Toxin and Tissue Fillers in Dental Practice”. 2015;3:1-16.

12. Sinha A, Hurakadli M, Yadav P. Botox and derma fillers: The twin face of cosmetic dentistry. Int J Contemp Dent Med Rev 2015; 2015: Article ID: 131214. DOI:10.15713/ins.ijcdmr.27.

13. Hwang et al. “Surface Anatomy of the lip elevator muscles for the treatment of gummy smile using botulinum toxin”. Angle Orthod. 2009; 79(1): 70-77.

14. Polo M. “Botulinum toxin Type A in the treatment of excessive gingival display”. Am J Orthod Dentofacial Orthop. 2005; 127 (2): 214-18.

15. Daines SM, Williams EF. “Complications associated with injectable soft-tissue fillers: a 5-year retrospective review”. JAMA Facial Plast Surg. 2013;15:226-31.

16. Nishimura K, Itoh T, Takaki K. et al. “Periodontal parameters of osseointegrated dental implants: A four-year controlled follow-up study. Clin Oral Implants Res. 1997;8:272-78.

17. Kayikvioglu A, Erk Y, Mavif E. et al. “Botulinum toxin in the treatment of zygomatic fractures”. Plast Reconstr Surg. 2003;111:341-46.

18. Van Zandijcke M, Marchau MM. “Treatment of bruxism with botulinum toxin injections”. J Neurol Neurosurg Psychiatry. 1990;53:530.

19. Ivanhoe CB, Lai JM, Francisco GE. “Bruxism after brain injury: Successful treatment with botulinum toxin-A”. Arch Phys Med Rehabil 1997; 78: 1272-3.

20. Castenada R. Occlusion. In: Kaplan A, Assael L (eds): Temporomandibular Disorders. Philadelphia, Pa: Saunders, 1992.

21. Freund B, Schwartz M, Symington JM. et al. “The use of botulinum toxin for the treatment of temporomandibular disorders: Preliminary findings”. J Oral Maxillofac Surg.1999; 57:916-21.

22. Brin MF, Fahn S, Moskowitz C. et al. “Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm”. Mov Disord. 1987;2:237-54.

23. Hermanowicz N, Truong DD. “Treatment of oromandibular dystonia with botulinum toxin”. Laryngoscope. 1991;101:1216-18.

24. Iankovic J, Orman J. “Botulinum toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study:. Neurology. 1987;27:616-23.

25. Tan EK, Jankovic J.”Botulinum toxin A in patients with oromandibular dystonia: Long-term follow-up”. Neurology. 1999;53:2102-07.

26. Laskawi R, Rohrbach S. “Oromandibular Dystonia: Clinical forms, diagnosis and examples of therapy with botulinum toxin”. Laryngorhinootologie. 2001;80:708-13.

27. Erdal J, Werdelin L, Prytz S. et al. “Experience with long-term botulinum toxin treatment of oromandibular dystonia, guided by quantitative EMG”. Acta Neurologica Scandinavica. 1996;94:210.

28. Cersosimo MG, Bertoti A, Roca CU, et al. “Botulinum toxin in a case of hemimasticatory spasm with severe worsening during pregnancy”. Clin Neuropharmacol. 2004;27:6-8.

29. Freund B, Schwartz M, Symington JM. “Botulinum Toxin: New treatment for temporomandibular disorders”. Br J Oral Maxillofac Surg 2000; 38: 466-71.

30. Glaros A, Tabacchi K, Glass EG. “Effect of parafunctional clenching on TMD pain and hearing loss”. J Orofacial Pain. 1998;12:145-52.

31. Farias A, Sushma R and Varma M. “Botulinum Toxin: A Peek at a Wonder Drug for Dentistry”. Sch. J. Dent. Sci. 2015; 2: 163-69.

32. Rao LB, Sangur R, Pradeep S. “Application of Botulinum toxin Type A: An arsenal in dentistry”. Indian J Dent Res. 2011;22:440-45.

33. Lim YC, Choi EC. “Treatment of an acute salivary fistula after parotid surgery: botulinum toxin Type A injection as primary treatment”. Eur Arch Otorhinolaryngol. 2008; 265:243-45.

34. Elcio JP. “BOTOX injections relieve severe facial pain”. Available from:http://www.news-medical.net/news/2005/10/25/14010.aspx.[last citedon 2009].

35. BOTOX. (Onabotulinum toxin A) Medication Guide: Initial U.S Approval, 1989.

36. Grover S, Malik V, Kaushik A, Diwakar R, Yadav P. “A future perspective of Botox in Dentofacial Region”. J Pharm Biomed Sci. 2014; 04:525-31.
Published
2018-03-24
Issue
Vol 2 No 1 (2018)
Section
Review Articles

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).